Varex Imaging: Undervalued Market Leader with Asymmetric Upside from Industrial Pivot
Overview
Varex Imaging Corporation is the largest independent supplier of X-ray tubes and digital detectors globally, serving a concentrated customer base of leading medical imaging OEMs. As of FY25, the company stands at a key inflection point, emerging from a turbulent period of supply chain shocks and Chinese market volatility with renewed operational momentum—demonstrated by outsized Q4 results. Its Medical segment, which anchors valuation, faces headwinds but benefits from recurring replacement cycles and moat-like regulatory protection. The Industrial segment is now the company’s growth engine, leveraging global investment in security and border infrastructure. Despite headline GAAP net losses due primarily to accounting impairments, underlying profitability and operating leverage remain strong, and recent strategic initiatives (new technology, cost base redesign, business diversification) are setting the stage for an earnings re-rating. Nevertheless, customer concentration and China exposure create structural vulnerabilities, leading the market to undervalue the company’s growth optionality. Varex presents an asymmetric opportunity for patient investors who can look past the headline risks towards embedded secular growth and margin expansion.